MRI‐guided interventional natural killer cell delivery for liver tumor treatment

Abstract

While natural killer (NK) cell‐based adoptive transfer immunotherapy (ATI) provides only modest clinical success in cancer patients. This study was hypothesized that MRI‐guided transcatheter intra‐hepatic arterial (IHA) infusion permits local delivery to liver tumors to improve outcomes during NK‐based ATI in a rat model of hepatocellular carcinoma (HCC). Mouse NK cells were labeled with clinically applicable iron nanocomplexes. Twenty rat HCC models were assigned to three groups: transcatheter IHA saline infusion as the control group, transcatheter IHA NK infusion group, and intravenous (IV) NK infusion group. MRI studies were performed at baseline and at 24 h, 48 h, and 8 days postinfusion. There was a significant difference in tumor R2* values between baseline and 24 h following the selective transcatheter IHA NK delivery to the tumors (P = 0.039) when compared to IV NK infusion (P = 0.803). At 8 days postinfusion, there were significant differences in tumor volumes between the control, IV, and IHA NK infusion groups (control vs. IV, P = 0.196; control vs. IHA, P < 0.001; and IV vs. IHA, P = 0.001). Moreover, there was a strong correlation between tumor R2* value change (∆R2*) at 24 h postinfusion and tumor volume change (∆volume) at 8 days in IHA group (R 2 = 0.704, P < 0.001). Clinically applicable labeled NK cells with 12‐h labeling time can be tracked by MRI. Transcatheter IHA infusion improves NK cell homing efficacy and immunotherapeutic efficiency. The change in tumor R2* value 24 h postinfusion is an important early biomarker for prediction of longitudinal response.

State of the Art of Natural Killer Cell Imaging: A Systematic Review

“…Su et al [73] studied the same route of administration in the same rodent model using NK cells labeled with FDA-approved SPIONs (Feraheme®). Labeled cells were injected through trans-catheter IHA infusion and MRI was performed at 24 h, 48 h and 8 days p.i.…”

Development of Spherical Nucleic Acids for Prostate Cancer Immunotherapy

“…On day 5, cells were harvested and CD8 + T cells were selected (Stemcell Technologies). The CTL cytotoxicity was evaluated by killing of target cells based on the apoptosis status of target cells ( 34 ). Purified CD8 + T cells were co-cultured with efluor450 (eBioscience) labeled target cells (5 × 10 3 ) at different effector to target (E/T) ratio in 96-well U-bottomed plate.…”

Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles

“…The local delivery of those modified NK cells and catalytic molecules for migration was also studied to enhance NK cell therapy approaches. Ultrasound-mediated-, magnetic field-mediated-, and catheter-directed-NK cell delivery have demonstrated improved NK cell homing and infiltration [54][55][56].…”